Periodic Adverse Drug Experience Report (PADER)
What is PADER?
Periodic Adverse Drug Experience Report (PADER) is a post-marketing safety report that pharmaceutical companies are required to submit to regulatory authorities such as the U.S. FDA after obtaining marketing approval. The primary purpose of PADER is to identify and evaluate potential new safety signals or adverse drug experiences associated with a product.
It provides a comprehensive summary of post-approval safety data, helping regulatory authorities assess the ongoing safety profile of a drug. PADER also supports the continuous evaluation of global safety information and offers insights that may lead to updates in product labeling or the need for additional investigations.
What are the specifications of PADER in pharma?
PADER includes a structured summary of adverse drug reactions and other safety-related information for a pharmaceutical product. It must be submitted by the sponsor or Marketing Authorization Holder (MAH) to the U.S. FDA after approval of a drug.
Key specifications include:
Reporting of both serious and non-serious adverse drug experiences
Periodic submission timelines (quarterly for the first 3 years, annually thereafter)
Inclusion of safety data from domestic and international sources
Narrative summaries and analysis of adverse events
Assessment of any significant changes in the benefit-risk profile
The regulatory basis for PADER is outlined in FDA 21 CFR Part 314.80, which defines requirements for post-marketing reporting of adverse drug experiences.
How does PADER ensure regulatory compliance?
PADER plays a critical role in ensuring regulatory compliance by enabling pharmaceutical companies to systematically monitor and report drug safety data. It supports compliance in the following ways:
Pharmacovigilance Compliance: Ensures continuous monitoring of drug safety in the post-marketing phase
Regulatory Reporting: Meets FDA requirements for periodic safety reporting
Signal Detection: Helps identify new or emerging risks associated with a drug
Risk Management: Supports timely actions such as label updates, warnings, or product recalls
Data Integrity and Traceability: Maintains accurate and auditable safety records
Modern pharmacovigilance systems and digital tools (such as safety databases and automated reporting systems) further enhance PADER processes by enabling efficient data collection, analysis, and submission.
Conclusion
PADER is a vital component of pharmacovigilance that ensures the ongoing safety and effectiveness of pharmaceutical products after they enter the market. By providing structured and periodic safety updates, it helps regulatory authorities and manufacturers maintain high standards of drug safety, protect public health, and ensure compliance with global regulatory requirements.